Prima BioMed Cash on Hand 2010-2021 | IMMP

Prima BioMed cash on hand from 2010 to 2021. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Prima BioMed Annual Cash on Hand
(Millions of US $)
2021 $45
2020 $18
2019 $12
2018 $18
2017 $9
2016 $15
2015 $6
2014 $19
2013 $31
2012 $39
2011 $55
2010 $14
2009 $1
Prima BioMed Quarterly Cash on Hand
(Millions of US $)
2017-03-31 $11
2016-12-31 $12
2016-06-30 $15
2015-12-31 $20
2015-06-30 $6
2014-12-31 $5
2014-06-30 $19
2013-12-31 $27
2013-06-30 $31
2012-12-31 $29
2012-06-30 $39
2011-06-30 $55
2010-06-30 $14
2009-06-30 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.174B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00